A summary of spasticity management – a treatment algorithm

European Journal of Neurology - Tập 9 Số s1 - Trang 48-52 - 2002
AB Ward1
1North Staffs Rehabilitation Centre, Haywood and Stanfield Hospital, Department of Rehabilitation Medicine, Stoke on Trent, UK

Tóm tắt

The muscle overactivity seen in spasticity results in limb stiffness and muscle spasm, to which there is both a neurogenic and a biomechanical component. Spasticity does not always cause harm and can assist in the rehabilitation process enabling a patient to stand when their limb weakness would not otherwise allow it. When it does cause harm, however, treatment is required. This aims to  (i) prevent provocative factors (ii) treat muscle overactivity; and (iii) prevent complications. Untreated, limb contracture, pain and other complications occur and early management can be most effective. Treatment is essentially physical, but, when this is inadequate, pharmacological intervention may be required. A strategy has been devised which shows that the first choice pharmacological treatment of focal spasticity is botulinum toxin. Over the past decade, the choice of treatment has become more ambitious with the establishment of new technologies. Good management now depends on an understanding of their role and application in relation to the needs of individual patients. To this end, a treatment algorithm which covers the salient facts in patient assessment and gives the indications for the range of available treatments, is the best approach. The indications and limitations of the available treatments are discussed, along with their place in the overall management of the patients. The evidence base for much of what is done is not strong and this summary examines the activities of proven value and of consensus view.

Từ khóa


Tài liệu tham khảo

Basmajan JV, 1975, Lioresal (baclofen) treatment of spasticity in multiple sclerosis, Am J Phy Med, 9, 175

Cosgrove AP, 1994, Botulinum toxin in the management of the lower limb in cerebral palsy, Dev Med Child Neurol, 9, 386, 10.1111/j.1469-8749.1994.tb11864.x

Cosgrove AP, 1994, Botulinum toxin prevents the development of contractures in the hereditary spastic mouse, Dev Med Child Neurol, 9, 379, 10.1111/j.1469-8749.1994.tb11863.x

From A, 1975, A double‐blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis, Acta Neurol Scand, 9, 158

10.1212/WNL.26.5.441

Levine IM, 1977, Lioresal, a new muscle relaxant in the treatment of spasticity: a double‐blind quantitative evaluation, Dis Nerv Sys, 9, 1011

10.1046/j.1468-1331.2002.0090s1017.x

Tardieu C, 1998, For how long must the soleus muscle be stretched each day to prevent contracture?, Dev Med Child Neurol, 9, 3

Thông tin
Thông tin xuất bản

European Journal of Neurology

Tập 9 Số s1

48-52

Thông tin tác giả